IGF-1 DES vs PEG-MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
IGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profilePEG-MGF
PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols.
Full profile| IGF-1 DES | PEG-MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 | PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout | 100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split) |
| Administration | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) | Subcutaneous injection (preferred for systemic distribution), Intramuscular injection |
| Key side effects | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses | Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: IGF-1 DES is research-stage, while PEG-MGF is preclinical only.
- Administration: IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect); PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
- Frequency: IGF-1 DES is typically 1–2x daily, preferably post-workout; PEG-MGF is 2x weekly (Monday/Thursday or similar split).
How each works
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
PEG-MGF
PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.